Document:

EX-10.28(xi)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(xi) 

AMENDMENT NO. 9 TO THE PROCESS DEVELOPMENT
AND CLINICAL SUPPLY AGREEMENT 
 THIS AMENDMENT
NO. 9 (the “Ninth Amendment”), effective as of November 26, 2012 (the “Ninth Amendment Effective Date”) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer
Straße 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered
into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment
No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7,
effective as of January 01, 2012, and Amendment No. 8 (which is under negotiation simultaneously) (hereinafter together the “Supply Agreement”). BI Pharma and FibroGen shall be referred to individually herein as a
“Party”, and collectively as the “Parties”. 
 WHEREAS, FibroGen and BI Pharma agreed to the work plan entitled
“[ * ] (Version of February 2, 2012)” and both parties are now in agreement that (i) some parts of this work plan have been successfully performed by BI Pharma, and (ii) some other parts need to be removed
from said work plan and be replaced by other work packages; 
 WHEREAS, FibroGen additionally wishes to engage BI Pharma to
[ * ], among others [ * ], in compliance with the terms of the Supply Agreement as amended by this Ninth Amendment. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties agree as follows: 
  

	 	(1)	Sections 2.1, 2.2 and 4 of the work plan entitled “[ * ] (Version of February 2, 2012)” shall be deleted. The other parts of this work plan, including those portions of the work plan
which have been performed by BI Pharma, shall remain in full force and effect. 

  

	 	(2)	Pursuant to Section 2.2 of the Supply Agreement, additional work packages shall be performed under the Agreement and therefore the Project shall be amended and replaced by the work plan entitled
“[ * ] (Version of November 26, 2012)”, which is attached hereto as Exhibit A and is hereby added as an amendment to Appendix 2 to the Supply Agreement. These additional work packages are 

 

	 	a)	[ * ] (as defined in the Sixth Amendment), [ * ] under the Seventh Amendment that are now deleted according to Section (1) of this Ninth Amendment, and 

 

	 	b)	[ * ], 

 in accordance with the Supply Agreement. 

 

	 	(3)	 This Ninth Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof.
Except as otherwise provided herein, the Supply Agreement has not been modified or amended and remains in full 

  
 1 

					
	Amendment No. 9 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

	 	
force and effect. All express or implied agreements and understandings that conflict with the terms of this Ninth Amendment, either oral or written, heretofore made with respect to subject matter
herein are expressly superseded by this Ninth Amendment. 

  

	 	(4)	This Ninth Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by
facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent. 

 IN WITNESS WHEREOF, the
Parties have executed this Ninth Amendment to the Supply Agreement as of Ninth Amendment Effective Date. 
 Biberach, February 21, 2013 

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 

 

							
	ppa.	 		  	ppa.	 	
				
	 [ * ]
	 		  	 [ * ]
	 	
	[ * ]	 		  	[ * ]	 	
	VP Business & Contracts	 		  	Head of Team Biberach – Dep. Legal Germany	 	

 San Francisco, March 25, 2013 

FIBROGEN, INC 
  

											
	 /s/ James Polarek
	 		 	  
	 	
	Name	 	 James W. Polarek
	 		 	Name	 	  
	 	
	Title	 	 VP, Protein Therapeutics and Collagen Development
	 		 	Title	 	  
	 	

  

					
		 	2	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	Amendment No. 9 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

Exhibit A 
 Work
Scope 
 (Version of November 26, 2012) 

[ * ] 

  

					
		 	3	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.28(xii)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(xii) 

AMENDMENT NO. 10 TO THE PROCESS DEVELOPMENT
AND CLINICAL SUPPLY AGREEMENT 
 THIS AMENDMENT
NO. 10 (the “Tenth Amendment”), effective as of June 21, 2013 (the “Tenth Amendment Effective Date”) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße
65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and
between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3,
effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective
as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012 and Amendment No. 9, effective as of November 26, 2012 (hereinafter together the “Supply Agreement”). BI Pharma and FibroGen shall be referred
to individually herein as a “Party”, and collectively as, the “Parties”. 
 WHEREAS, FibroGen wishes to engage BI
Pharma to [ * ], in compliance with the terms of the Supply Agreement as set forth in and as amended by this Tenth Amendment. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties agree as follows: 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this Tenth Amendment shall have the meaning ascribed to them in the Supply Agreement. 

 

	 	(2)	The Parties agree that pursuant to Section 2.2 of the Supply Agreement, the work plan entitled “[ * ], Version of April 19, 2013”, attached hereto as Exhibit A, is hereby
added as an Amendment to Appendix 2 to the Supply Agreement. Pursuant thereto BI Pharma shall, on behalf of FibroGen, manufacture in accordance with the Supply Agreement, (i) [ * ] (as defined in the Amended and Restated
Quality Agreement between the Parties dated March 03, 2011 (hereinafter “Amended and Restated Quality Agreement”), (ii) [ * ] (as defined in the Amended and Restated Quality Agreement) [ * ], and
(iii) [ * ]. The term [ * ] shall mean [ * ] for clinical supply that [ * ] agreed upon between the Parties in writing. 

 

	 	(3)	The Specifications for [ * ] pursuant to Section 2 hereof have been agreed to by the Parties and are set forth in the Amended and Restated Quality Agreement by and between the Parties. Such
Specifications for [ * ], as applicable, shall apply to the activities contemplated by Section (2) above as part of the Acceptance Criteria for [ * ], respectively. 

 

	 	(4)	All provisions of the Supply Agreement relating to the manufacture of Product which are reasonably applicable to [ * ] shall apply accordingly to such [ * ] as set forth in Exhibit
A hereto, including but not limited the provisions regarding delivery of Product set forth in Section 4 of the Supply Agreement, Parties’ warranties set forth in Section 7 of the Supply Agreement (including, for the avoidance of
doubt, the disclaimer set forth in Section 7.5 of the Supply Agreement) and the limitations of the Parties’ liability and indemnification obligations set forth in Section 8 of the Supply Agreement. 

					
	Amendment No. 10 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

 

	 	(5)	This Tenth Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Supply Agreement has not
been modified or amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this Tenth Amendment, either oral or written, heretofore made with respect to subject matter herein
are expressly superseded by this Tenth Amendment. 

  

	 	(6)	This Tenth Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by
facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent. 

 IN WITNESS WHEREOF, the
Parties have executed this Tenth Amendment to the Supply Agreement as of Tenth Amendment Effective Date. 
 Biberach, June 21, 2013 

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 

 

							
	ppa.	 		  	i.V.	  	
				
	 [ * ]
	 		  	 [ * ]
	  	
	[ * ]	 		  	[ * ]	  	
	Head of Corporate Legal Biopharma	  	Dir. Business & Contracts	  	

  

							
	San Francisco                     ,2013	 		  	
			
	FIBROGEN, INC	 		  	
			
	 /s/ Jim Polarek
	 		  	
	Name	 	 Jim Polarek
	 		  	
	Title	 	 Vice President
	 		  	

  

					
		 	2	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	Amendment No. 10 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

Exhibit A 
 Work
Scope 
 (Version of April 19, 2013) 

[ * ] 

  

					
		 	3	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]